Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: metformin;   Drug: ipragliflozin;   Drug: glimepride
Sponsor:   Astellas Pharma Korea, Inc.
Recruiting - verified April 2017

The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

Conditions:   Type 2 Diabetes Mellitus;   Hypertriglyceridemia
Interventions:   Drug: Omega-3 fatty acid;   Drug: Placebos
Sponsor:   Shanghai Jiao Tong University School of Medicine
Recruiting - verified April 2017

Taking on Diabetes to Advance You (TODAY)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Taking on Diabetes to Advance You (TODAY) Project
Sponsor:   Arlene Schmid
Recruiting - verified April 2017

Microbiome Insulin Sensitivity Study

Conditions:   Obesity;   Insulin Resistance;   Type2 Diabetes
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institutes of Health (NIH);   Children's Hospital Colorado
Not yet recruiting - verified April 2017

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Sitagliptin;   Drug: Placebo for sitagliptin;   Drug: Placebo for bexagliflozin
Sponsor:   Theracos
Not yet recruiting - verified April 2017

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY3325656;   Drug: Placebo;   Drug: Liraglutide;   Drug: Sitagliptin
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2017

Impact of Empaglifozine on Cardiac Ectopic Fat

Condition:   Type 2 Diabetes
Intervention:   Drug: Empagliflozin 10Mg Tab
Sponsor:   Assistance Publique Hopitaux De Marseille
Not yet recruiting - verified April 2017

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

Condition:   PCOS
Interventions:   Drug: Sitagliptin;   Behavioral: Lifestyle intervention
Sponsor:   University Medical Centre Ljubljana
Completed - verified April 2017

Intensive Uric Acid Lowering With RDEA3170 and Febuxostat in Chronic Kidney Disease

Conditions:   Hyperuricemia;   Mild to Moderate Chronic Kidney Disease;   Type 2 Diabetes
Interventions:   Drug: RDEA3170 9 mg+Febuxostat 80 mg;   Drug: Placebo
Sponsor:   AstraZeneca
Not yet recruiting - verified April 2017

Endoscopic Sleeve Gastroplasty for Morbid Obesity

Condition:   Endoscopic Sleeve Gastroplasty
Interventions:   Procedure: Endoscopic Sleeve Gastroplasty;   Procedure: Laparoscopic Sleeve Gastrectomy
Sponsor:   Chinese University of Hong Kong
Not yet recruiting - verified April 2017

Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation

Conditions:   Type 2 Diabetes Mellitus;   Colonoscopy
Intervention:   Drug: Colonoscopy preparation using polyethylene glycol
Sponsor:   Catholic Kwandong University
Recruiting - verified April 2017

Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors

Conditions:   Cancer Survivor;   Central Obesity;   No Evidence of Disease
Interventions:   Other: Best Practice;   Behavioral: Exercise Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   University of Southern California;   National Cancer Institute (NCI)
Not yet recruiting - verified April 2017

Basal Insulin Strategies Before Surgery

Condition:   Type2 Diabetes Mellitus
Intervention:   Other: 25% reduction of basal insulin dose
Sponsor:   Ohio State University
Active, not recruiting - verified April 2017

Changes in Ingestive Behaviour Following Gastric Bypass

Condition:   Morbid Obesity
Intervention:  
Sponsors:   University of Ulster;   University College Dublin;   University of Florida;   Letterkenny University Hospital
Recruiting - verified April 2017

De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women

Conditions:   Diabetes;   Weight Loss;   PreDiabetes;   Obesity
Intervention:   Behavioral: Behavioural Lifestyle Intervention
Sponsors:   Kaiser Permanente;   Arizona State University
Active, not recruiting - verified April 2017

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Use of digital disease management tool
Sponsor:   AstraZeneca
Not yet recruiting - verified April 2017

Mechanisms of Age-Related Muscle Loss

Conditions:   Sarcopenic Obesity;   Muscle Weakness;   Protein Metabolism Disorder;   Physical Activity
Intervention:  
Sponsor:   University of Birmingham
Completed - verified April 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec;   Drug: Insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Mobile health system;   Other: E-mail reports and technical support for mHealth system
Sponsors:   University of Michigan;   Mahidol University;   John E. Fogarty International Center (FIC)
Not yet recruiting - verified April 2017

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: IW-1973 Oral Tablet;   Drug: IW-1973 Oral Tablet;   Drug: Placebo Oral Tablet
Sponsor:   Ironwood Pharmaceuticals, Inc.
Recruiting - verified April 2017

Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: No Treatment
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Conditions:   Type2 Diabetes;   Dyslipidemia
Interventions:   Drug: K-877;   Drug: Placebo
Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
Recruiting - verified April 2017

Cold Induced Activation of Brown Adipose Tissue in Winter Swimmers

Conditions:   Adipose Tissue;   Brown Adipose Tissue;   Brown Fat;   Uncoupling Protein 1;   Adipokines;   Proteomics;   Infra-red Thermography;   BAT;   Winter Swimmers;   Type2 Diabetes;   Proteins
Intervention:   Procedure: Cooling
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified April 2017

Cold Induced Activation of Brown Adipose Tissue in Humans

Conditions:   Adipose Tissue, Brown;   Brown Adipose Tissue;   Brown Fat;   Uncoupling Protein 1;   Adipokines;   Proteomics;   Infrared Thermography;   BAT;   Obesity;   Type 2 Diabetes;   Proteins
Interventions:   Procedure: Cooling;   Procedure: Thermoneutral
Sponsor:   Susanna Søberg
Recruiting - verified April 2017

A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Analog Mid Mixture;   Drug: Basal Insulin Analog
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

Conditions:   Diabetes Mellitus;   Alzheimer Dementia
Intervention:   Drug: 18F-THK-5351
Sponsors:   Columbia University;   National Institute on Aging (NIA)
Not yet recruiting - verified April 2017

A Mobile Phone-based Program for Adults With Prediabetes

Conditions:   Prediabetic State;   Diabetes Mellitus
Intervention:   Device: JOOL Health Mobile Phone Application
Sponsors:   University of Michigan;   Blue Cross Blue Shield of Michigan Foundation
Not yet recruiting - verified April 2017

Episodic to Real-Time Care in Diabetes Self-Management

Condition:   Diabetes Mellitus, Type II
Intervention:   Behavioral: Type 2 Diabetes Self-Management
Sponsor:   Duke University
Enrolling by invitation - verified April 2017

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Conditions:   Steatosis, Liver;   Type2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Exenatide matching Placebo;   Drug: Dapagliflozin
Sponsors:   Medical University of Vienna;   AstraZeneca
Recruiting - verified April 2017

Effects of Acute High Intensity Exercise Training on Cardiac Function in Type II Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: high intensity interval training
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified April 2017

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified April 2017

Get In Touch Phase 2

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Livongo for Diabetes program
Sponsors:   University of Massachusetts, Worcester;   Livongo Health
Active, not recruiting - verified April 2017

Identifying Therapeutic Targets of Accelerated Sarcopenia

Conditions:   Sarcopenia;   Diabetes Mellitus;   Aging
Interventions:   Behavioral: Resistance exercise training;   Behavioral: Bed rest;   Behavioral: Intensive physical therapy
Sponsors:   The University of Texas Medical Branch, Galveston;   National Institute on Aging (NIA)
Not yet recruiting - verified April 2017

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2017

Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Drug: Metformin and Liraglutide
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified November 8, 2016

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time

Condition:   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified April 2017

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Diabetes Engagement and Activation Platform

Condition:   Type 2 Diabetes (T2D)
Intervention:   Other: Usual Care
Sponsor:   Virginia Commonwealth University
Not yet recruiting - verified April 2017

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Metformin;   Drug: Glimepiride;   Drug: Sitagliptin
Sponsor:   Theracos
Completed - verified April 2017

Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Device: Insulin Pump;   Drug: Multiple daily injections of insulin
Sponsors:   Clinical Research Centre, Malaysia;   Medtronic
Recruiting - verified April 2017

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster Aspart;   Drug: Insulin Aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Sulfonylurea;   Drug: metformin;   Drug: basal insulin
Sponsor:   Sanofi
Recruiting - verified April 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Drug-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified April 2017

Effect of Nutritional Products in Subjects With Type 2 Diabetes

Condition:   Diabetes
Interventions:   Other: Standard ONS;   Other: Diabetes specific ONS 1;   Other: Diabetes specific ONS 2
Sponsor:   Abbott Nutrition
Completed - verified April 2017

Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Marker of the Cellular Captation of Glucose: the IRAP Protein

Condition:   Insulin Resistance
Intervention:   Other: Blood sample collection during an OGTT to assess IRAP blood concentration
Sponsor:   University Hospital, Grenoble
Recruiting - verified April 2017

Enhancing mHealth Technology to Activate Chronic Care Patients

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Mobile Health Care Environment (MHCE)
Sponsors:   Clemson University;   Madigan Army Medical Center;   U.S. Army Medical Research and Materiel Command
Recruiting - verified April 2017

Preprandial Ghrelin Effect

Condition:   Type 2 Diabetes
Interventions:   Drug: ghrelin;   Other: Saline
Sponsors:   Jenny Tong, MD, MPH;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2017

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Conditions:   Poor Glycemic Control;   Cardiovascular Risk Factors;   Cognitive Function 1, Social
Interventions:   Dietary Supplement: carnosine;   Drug: Placebo
Sponsor:   Monash University
Recruiting - verified April 2017

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Conditions:   Type 2 Diabetes Mellitus;   Heart Failure
Interventions:   Drug: Saxagliptin;   Drug: Sitagliptin;   Drug: Placebo to match saxagliptin;   Drug: Placebo to match sitagliptin
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2017

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   PAREXEL International GmbH;   Spandauer Damm 130;   14050;   Berlin, Germany
Recruiting - verified April 2017

Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Low intensity therapeutic ultrasound
Sponsor:   Universidade Federal de Santa Maria
Recruiting - verified January 2017

Effect of DMR Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Conditions:   Diabetes Mellitus, Type 2;   Noninsulin-Dependent Diabetes Mellitus
Interventions:   Procedure: DMR Procedure;   Procedure: Sham Procedure
Sponsor:   Fractyl Laboratories, Inc.
Recruiting - verified April 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept

Condition:   Type 2 Diabetes
Intervention:   Other: Biopsy
Sponsor:   University Hospital, Toulouse
Recruiting - verified April 2017

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified April 2017

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified April 2017

Study to Evaluate CORT125134 in Patients With Cushing's Syndrome

Condition:   Cushing's Syndrome
Intervention:   Drug: CORT125134
Sponsor:   Corcept Therapeutics
Recruiting - verified April 2017

Meta-analyses of the Effect of 'Catalytic' Doses of Fructose and Its Epimers on Carbohydrate Metabolism

Conditions:   Overweight;   Obesity;   Dysglycemia;   Prediabetes;   Metabolic Syndrome;   Type 2 Diabetes
Intervention:   Other: fructose, allulose, tagatose, or sorbose
Sponsors:   University of Toronto;   Canadian Diabetes Association;   The Physicians' Services Incorporated Foundation;   Banting & Best Diabetes Centre;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified April 2017

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo for Bexagliflozin;   Drug: Glimepiride;   Drug: Placebo for Glimepiride
Sponsor:   Theracos
Recruiting - verified April 2017

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified April 2017

ForgIng New Paths to Prevent DIabeTes (FINDIT)

Condition:   Prediabetes
Interventions:   Behavioral: Blood Test Group Intervention;   Behavioral: Brochure Group Intervention
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified April 2017

Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: VEMOFIT;   Behavioral: Attention-meetings (AG)
Sponsors:   Universiti Putra Malaysia;   Ministry of Health, Malaysia;   UMC Utrecht
Enrolling by invitation - verified April 2017

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Active, not recruiting - verified April 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No Intervention
Sponsor:   Janssen Inc.
Active, not recruiting - verified April 2017

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2017

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Condition:   Type 2 Diabetes Mellitus (T2DM)
Intervention:   Behavioral: Lifestyle intervention
Sponsor:   Novartis Pharmaceuticals
Completed - verified April 2017

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2017

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention
Sponsor:   Janssen Research & Development, LLC
Completed - verified April 2017

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Standard of Care
Sponsors:   AstraZeneca;   Quintiles, Inc.;   Clinical Practice Research Datalink
Recruiting - verified April 2017

Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury

Conditions:   Spinal Cord Injury;   Paraplegia;   Tetraplegia
Intervention:   Device: Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)
Sponsor:   University of Manitoba
Enrolling by invitation - verified April 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified April 2017

Fish or Nuts? Dietary Effects on Cardiometabolic Risk Factors and Persistent Organic Pollutants

Conditions:   Obesity;   Metabolic Syndrome;   Diabetes
Interventions:   Other: The fatty fish group;   Other: The nut group;   Other: The control group
Sponsor:   Oslo University Hospital
Recruiting - verified April 2017

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents

Condition:   Diabetes Mellitus, Type 2 (T2DM)
Interventions:   Device: Bolus Insulin Patch (Calibra Finesse);   Device: Insulin Pen (Novo-Nordisk FlexPen®)
Sponsors:   Calibra Medical, Inc.;   Medpace, Inc.
Active, not recruiting - verified April 2017

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Conditions:   Type 2 Diabetes;   Metabolic Syndrome
Intervention:   Drug: PBI4050
Sponsor:   ProMetic BioSciences Inc.
Completed - verified October 2016

Improving Chronic Disease Management With Pieces

Conditions:   Chronic Kidney Disease;   Diabetes;   Hypertension;   High BP;   Type 2 Diabetes
Intervention:   Other: Collaborative Model of Primary care and Subspecialty care
Sponsors:   University of Texas Southwestern Medical Center;   Parkland Center for Clinical Innovation;   Parkland Health & Hospital System;   Texas Health Resources;   Connecticut Center for Primary Care;   Dallas VA Research Corporation;   G-Health Enterprises
Recruiting - verified April 2017

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Active, not recruiting - verified April 2017

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease

Conditions:   Alzheimer´s Disease;   Diabetes Mellitus Type 2
Intervention:   Other: There is a retrospectiv observational study. No intervention
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Completed - verified April 2017

Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   Ain Shams University
Recruiting - verified April 2017

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified April 2017

Ghrelin and Beta Cell Function in Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Synthetic human AG;   Drug: Arginine;   Drug: 0.9% saline solution
Sponsors:   Jenny Tong, MD, MPH;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2017

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:   Drug: Icosapent ethyl
Sponsor:   Brigham and Women's Hospital
Terminated - verified April 2017

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Conditions:   Diabetes;   PTH;   Vitamin D;   Fibroblast Growth Factor (FGF23);   Phosphate
Interventions:   Drug: Placebo;   Drug: Canagliflozin
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 31, 2017

Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease

Conditions:   Retinal Neurodegeneration;   Alzheimer´s Disease;   Type 2 Diabetes
Intervention:  
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Completed - verified April 2017

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: Roflumilast/Sitagliptin;   Drug: Sitagliptin;   Drug: Roflumilast
Sponsor:   National Institute on Aging (NIA)
Completed - verified September 19, 2016

Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus

Conditions:   Thrombosis;   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Primrose oil;   Dietary Supplement: Fish Oil
Sponsors:   University of Michigan;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified April 2017

Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function

Condition:   Platelet Aggregation During Acute Myocardial Infarction
Interventions:   Drug: saxagliptin;   Drug: placebo
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute
Recruiting - verified January 2017

The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Interventions:   Drug: RTA 402;   Drug: Placebo
Sponsor:   Kyowa Hakko Kirin Co., Ltd
Active, not recruiting - verified April 2017

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Active, not recruiting - verified July 2016

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2 With Hyperglycemia
Interventions:   Drug: Hydroxychloroquine;   Drug: Pioglitazone
Sponsor:   Charles Drew University of Medicine and Science
Recruiting - verified April 2017

Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

Condition:   Epithelial Ovarian Cancer
Interventions:   Drug: Metformin;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   University Medical Center Groningen
Recruiting - verified April 2017

Hartmann's Solution and Normal Saline in Type II Diabetes Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Hartmann's solution;   Drug: Normal saline
Sponsor:   Yeungnam University College of Medicine
Withdrawn - verified April 2017

Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Other: ADR-1;   Other: GMNL-263;   Other: placebo
Sponsor:   GenMont Biotech Incorporation
Recruiting - verified April 2017

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Active, not recruiting - verified April 2017

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: NPH and regular insulin;   Drug: glargine and humalog
Sponsor:   Riverside County Regional Medical Center
Terminated - verified April 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2017

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Condition:   Type II Diabetes Mellitus
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diabetes Care Deutschland GmbH
Completed - verified April 2017

Peer Support for Achieving Independence in Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Community Health Worker Intervention
Sponsors:   Public Health - Seattle and King County;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 2017

Fat Metabolism in OSA and COPD

Conditions:   Obstructive Sleep Apnea;   Chronic Obstructive Pulmonary Disease;   Obesity
Intervention:  
Sponsor:   Texas A&M University
Recruiting - verified April 2017

Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Culturally tailored diabetes program
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2017

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Condition:   Insulin Sensitivity
Interventions:   Drug: Maltodextrin;   Drug: Synbiotic;   Drug: Sevelamer
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association
Recruiting - verified April 2017

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 22, 2016

Effects of Sedentary Behaviour on Metabolic Parameters

Conditions:   Sedentary Lifestyle;   Type 2 Diabetes
Interventions:   Other: Inactivity;   Other: Activity
Sponsor:   University of British Columbia
Recruiting - verified April 2017

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus Type 2 (T2DM);   Vascular Inflammation;   Plaque Morphology
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   RWTH Aachen University
Terminated - verified December 2015

ADA Linagliptin in Long Term Care

Condition:   Diabetes
Interventions:   Drug: linagliptin;   Drug: insulin glargine
Sponsors:   Emory University;   American Diabetes Association
Completed - verified April 2017

Metformin in the Diastolic Dysfunction of Metabolic Syndrome

Conditions:   Metabolic Syndrome X;   Diastolic Dysfunction;   Insulin Resistance
Interventions:   Behavioral: Lifestyle Counseling;   Drug: Metformin
Sponsors:   Universidade do Porto;   Centro Hospitalar de Vila Nova de Gaia/Espinho;   Merck Serono International SA
Active, not recruiting - verified April 2017

Hypoglycemia (Low Blood Sugar) and the Heart

Conditions:   Hypoglycemia;   Type 2 Diabetes
Intervention:  
Sponsors:   University of British Columbia;   icentia
Recruiting - verified April 2017

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified November 18, 2016

Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs

Conditions:   Pre-diabetic;   Diabetic Type II Mellitus
Intervention:   Behavioral: Ottawa Model for Smoking Cessation
Sponsor:   Ottawa Heart Institute Research Corporation
Completed - verified January 2017

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Completed - verified April 2017

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Plant-Based Dietary Intervention in Type 2 Diabetes-2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Low-fat, low-Glycemic Index, vegan diet;   Behavioral: ADA diet
Sponsors:   Physicians Committee for Responsible Medicine;   George Washington University
Suspended - verified April 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified April 2017

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus Type 2 (T2DM);   Left Ventricular Diastolic Dysfunction
Interventions:   Drug: Linagliptin;   Drug: placebo
Sponsor:   RWTH Aachen University
Terminated - verified February 2015

Mechanisms of Diabetic Kidney Disease in American Indians

Conditions:   Nervous System;   Diabetic Kidney Disease;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation - verified February 28, 2017

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified April 2017

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 9, 2017

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017

Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix

Conditions:   Obesity;   Diet Therapy;   Diabetes Type 2
Intervention:   Behavioral: Controlling Gestational Weight Gain
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 27, 2017

RISE Pediatric Medication Study

Conditions:   Prediabetes;   Type 2 Diabetes
Interventions:   Drug: Metformin;   Drug: Glargine
Sponsors:   RISE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2017

The Health Influences of Puberty (HIP) Study

Conditions:   Obesity;   Insulin Resistance;   Gonadal Dysfunction;   Type 2 Diabetes
Intervention:   Drug: Metformin
Sponsors:   University of Colorado, Denver;   American Diabetes Association;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Children's Hospital Colorado
Active, not recruiting - verified April 2017

The Microvascular Function of GLP-1 and Its Analogues

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: GLP-1;   Drug: Placebo
Sponsors:   Katarina Kos;   Diabetes UK
Completed - verified April 2017

Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics

Conditions:   Smoking;   Diabetes
Intervention:   Procedure: Dental implant surgery
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Dental and Craniofacial Research (NIDCR);   National Center for Research Resources (NCRR)
Recruiting - verified April 2017

Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Procedure: Gastric Bypass w/ matched hypocaloric diet;   Other: Hypocaloric diet
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   American Diabetes Association
Recruiting - verified April 2017

Mindfulness: a Novel Approach for the Management of Diabetes-related Distress

Conditions:   Emotional Distress;   Type 2 Diabetes;   Stress
Intervention:   Behavioral: Mindfulness Based Stress Reduction
Sponsor:   University of North Carolina, Chapel Hill
Completed - verified April 2017

Examining The Role of CGM in T2DM

Condition:   DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Intervention:   Other: Continuous Glucose Monitoring with treatment algorithm
Sponsors:   University of North Carolina, Chapel Hill;   Medtronic;   Atlanta Diabetes Associates;   UNC Coordinating Center
Completed - verified July 2015

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Global SYMPLICITY Registry

Conditions:   Hypertension;   Diabetes Mellitus;   Heart Failure;   Chronic Kidney Disease;   Sleep Apnea
Intervention:   Device: Medtronic Renal Denervation System
Sponsor:   Medtronic Vascular
Recruiting - verified April 2017

Pioglitazone to Treat Opioid Withdrawal Symptoms

Condition:   Opioid-Related Disorders
Interventions:   Drug: Pioglitazone;   Drug: Placebo
Sponsor:   National Institute on Drug Abuse (NIDA)
Terminated - verified February 2, 2015

Smoking Cessation Intervention for Diabetic Patients

Conditions:   Smoking;   Type 2 Diabetes
Interventions:   Behavioral: Acceptance and Commitment Therapy;   Behavioral: Standard smoking cessation intervention
Sponsor:   Rhode Island Hospital
Completed - verified April 2017

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Completed - verified January 27, 2016

Mifepristone for Metabolic Syndrome

Conditions:   Endocrine Disease;   Diabetes
Intervention:   Drug: Mifepristone
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 16, 2016

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation - verified September 26, 2016

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified April 2017

Insulin Detemir in Obesity Management

Conditions:   Diabetes;   Obesity
Intervention:   Drug: Detemir
Sponsors:   Vanderbilt University;   Novo Nordisk A/S
Active, not recruiting - verified April 2017

Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction

Condition:   Diabetes Type 2
Intervention:   Other: Exercise
Sponsor:   Norwegian University of Science and Technology
Completed - verified April 2017

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: vildagliptin/metformin
Sponsor:   Novartis
Completed - verified February 2017

Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 4, 2016

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Conditions:   Diabetic Retinopathy;   Diabetic Macular Edema
Intervention:  
Sponsor:   National Eye Institute (NEI)
Terminated - verified August 7, 2013

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 23, 2016

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

Conditions:   Obesity;   Bariatric Surgery;   Morbid Obesity;   Diabetes Mellitus Type 2;   Diet Therapy
Interventions:   Procedure: Roux-en-Y Gastric Bypass;   Behavioral: Caloric Restriction
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 3, 2017

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Completed - verified April 2017

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 14, 2016

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

Condition:   Nonalcoholic Steatohepatitis
Interventions:   Drug: pioglitazone-placebo;   Drug: pioglitazone;   Dietary Supplement: Vitamin E;   Drug: pioglitazone-placebo;   Dietary Supplement: Vitamin E;   Drug: Vitamin E-placebo
Sponsor:   VA Office of Research and Development
Completed - verified April 2017

Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics

Conditions:   At-risk Drinking;   Type 2 Diabetes
Interventions:   Behavioral: Brief alcohol intervention;   Behavioral: General health education
Sponsor:   Rhode Island Hospital
Completed - verified April 2016

Natural History of Autoimmune Diabetes and Its Complications

Conditions:   Type 1 Diabetes;   Type 2 Diabetes;   Immunologically Mediated Type 1 Diabetes;   Anti Beta-Cell Autoantibodies;   Autoimmunity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 16, 2017

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Conditions:   Diabetes;   Obesity;   Healthy Volunteers
Interventions:   Dietary Supplement: Vitamin E;   Dietary Supplement: Vitamin C
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 7, 2016

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Conditions:   Weight Loss;   Obesity
Interventions:   Drug: Byetta (exenatide);   Behavioral: Weight loss;   Other: Metabolic Chamber;   Drug: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified September 19, 2016

Genetics of Type 2 Diabetes Among Han Chinese

Conditions:   Diabetes;   Obesity;   Hypertension;   Retinopathy;   Nephropathy
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified September 14, 2016

Genetics of Type 2 Diabetes in West Africans

Conditions:   Hypertension;   Diabetes
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified November 15, 2016

Home-Based Walking Study in Older Adults With Type 2 Diabetes

Conditions:   Cardiovascular;   Diabetes;   Orthostatic Hypotension;   Type 2 Diabetes
Intervention:   Behavioral: Control Phase; Exercise Phase
Sponsor:   University of British Columbia
Completed - verified April 2017

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

Conditions:   Diabetes Mellitus Type 1;   Diabetes Mellitus Type 2
Intervention:   Drug: Sitagliptin (Januvia)
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 16, 2017

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Completed - verified April 2017

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Conditions:   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus;   Moderate Chronic Obstructive Pulmonary Disease;   Asthma
Interventions:   Drug: Technosphere® Insulin;   Drug: Usual Care
Sponsor:   Mannkind Corporation
Terminated - verified April 2017

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

Conditions:   Obesity;   Overweight;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 27, 2016

Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes

Conditions:   Cardiovascular;   Diabetic
Interventions:   Behavioral: Aerobic Exercise and Strength Exercise;   Behavioral: Strength training
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
Completed - verified April 2017

Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

Condition:   Non-Insulin Dependent Diabetes Mellitus
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified December 14, 2016

Fat Cell Size in Insulin Resistance

Conditions:   Obesity;   Adipose Cell Turn Over
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 22, 2016

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

Condition:   Diabetes
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 16, 2017

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 16, 2017

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions:   Diabetic Nephropathy;   Diabetes Mellitus;   Diabetic Kidney Disease;   Albuminuria
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 24, 2017

A Study of the Function of Hormones Present In Taste Buds

Conditions:   Diabetes;   Obesity;   Pre-Diabetes;   Metabolic Syndrome
Intervention:  
Sponsor:   National Institute on Aging (NIA)
Completed - verified January 2, 2015

Feasibility Study of Digital Photography and Group Discussion for People With Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Digital Photography of meals/snacks and group discussion
Sponsors:   Joslin Diabetes Center;   Beth Israel Deaconess Medical Center
Terminated - verified April 2017

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Conditions:   Diabetes Mellitus;   Obesity
Intervention:   Procedure: Oral glucose tolerance test
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 29, 2016